# US 8,278,421 B2 · Human antibodies specific for gastrin materials and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,421 B2
- Document ID: US8278421B2
- Status: Granted
- Kind: B2
- Application number: 12/293,890
- Filed: 2006-12-13
- Published: 2009-12-17
- Granted: 2012-10-02
- Earliest claimed: 2006-03-20
- Assignees: Xoma Techolology Ltd.
- Inventors: Linda Masat; Marina Roell
- Web page: https://patentgrep.com/patent/US8278421B2

## CPC

- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.

## Claims

### Claim 1

An isolated antibody that binds gastrin (gastrin 17) with an affinity kd of 10−7 M or less that comprises:
(a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33, a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
(b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution or a consensus sequence thereof;
(c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33 or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
(d) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
(e) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution; and
(f) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution.

### Claim 2 (depends on 1)

The antibody of claim 1 wherein one or more of said heavy chain CDR1, CDR2 or CDR3 amino acid sequences is a consensus sequence set forth in SEQ ID NO: 11.

### Claim 3 (depends on 1)

The antibody of claim 1 wherein
(a) an amino acid in a heavy chain CDR1 amino acid sequence is replaced with an amino acid from a corresponding position within a different heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33; or
(b) an amino acid in a heavy chain CDR2 amino acid sequence is replaced with an amino acid from a corresponding position within a different heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33; or
(c) an amino acid in a heavy chain CDR3 amino acid sequence is replaced with an amino acid from a corresponding position within a different heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33.

### Claim 4 (depends on 1)

The antibody of claim 1 that comprises a heavy chain variable region amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33.

### Claim 5 (depends on 1)

The antibody of claim 1 in which one or more heavy chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

### Claim 6 (depends on 1)

The antibody of claim 1 further comprising a human heavy chain constant region attached to said heavy chain variable region.

### Claim 7 (depends on 1)

The antibody of claim 1 wherein one or more of said light chain CDR1, CDR2 or CDR3 amino acid sequences is a consensus sequence set forth in SEQ ID NO: 12.

### Claim 8 (depends on 1)

The antibody of claim 1 wherein
(a) an amino acid in a light chain CDR1 amino acid sequence is replaced with an amino acid from a corresponding position within a different light chain CDR1 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12; or
(b) an amino acid in a light chain CDR2 amino acid sequence is replaced with an amino acid from a corresponding position within a different light chain CDR2 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12; or
(c) an amino acid in a light chain CDR3 amino acid sequence is replaced with an amino acid from a corresponding position within a different light chain CDR3 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12.

### Claim 9 (depends on 1)

The antibody of claim 1 that comprises a light chain variable region amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12.

### Claim 10 (depends on 1)

The antibody of claim 1 in which one or more light chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

### Claim 11 (depends on 1)

The antibody of claim 1 further comprising a human light chain constant region attached to said light chain variable region.

### Claim 12 (depends on 1)

An antibody of claim 1 that exhibits at least 70% neutralization of calcium flux in an assay using AGS-TR cells, wherein the tested antibody is at a concentration in 100 molar excess over gastrin, and wherein gastrin is at the EC50 concentration (1 nM).

### Claim 13 (depends on 1)

The antibody of claim 1 that comprises 6 CDRs of any of XPA061 (SEQ ID NO: 1 and 2), XPA063 (SEQ ID NO: 3 and 4), XPA065 (SEQ ID NO: 5 and 6), XPA067 (SEQ ID NO: 7 and 8), and XPA081 (SEQ ID NO: 9 and 10).

### Claim 14 (depends on 1)

The antibody of claim 1 which is a single chain antibody.

### Claim 15 (depends on 1)

The antibody of claim 1 that is conjugated to another diagnostic or therapeutic agent.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 4)

A kit comprising an antibody of claim 4 and instructions for use.

### Claim 18

An isolated monoclonal antibody that binds gastrin (gastrin 17) with an affinity kd of 10−8 M or less that comprises:
(a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33, a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
(b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution or a consensus sequence thereof;
(c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11 or 23-33, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution, or a consensus sequence thereof;
(d) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution;
(e) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution; and
(f) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs: 2, 4, 6, 8, 10 or 12, or a variant thereof in which one or two amino acids have been changed by conservative amino acid substitution.

### Claim 19 (depends on 1)

The antibody of claim 1 wherein the heavy chain CDR2 and CDR3 amino acid sequences are from the same heavy chain variable region as the CDR1 amino acid sequence.

### Claim 20 (depends on 1)

The antibody of claim 1 wherein the light chain CDR2 and CDR3 amino acid sequences are from the same light chain variable region as the CDR1 amino acid sequence.

### Claim 21 (depends on 1)

The antibody of claim 1 that comprises heavy chain CDR1, CDR2 and CDR3 of any of XPA067.06 (SEQ ID NO: 23) and XPA067.18 (SEQ ID NO: 29).

### Claim 22 (depends on 16)

A method for treating a condition or disorder selected from the group consisting of pancreatic cancer, esophageal cancer, gastric cancer, colorectal cancer, small lung cell carcinoma, gastric ulcer, duodenal ulcer, other ulcers or conditions associated with H. Pylori, gastroesophageal reflux disease, autoimmune gastritis, atrophic body gastritis, Zollinger-Ellison syndrome associated with tumor of the pancreas (gastrinoma), or inflammatory bowel disease comprising the step of administering to a subject in need a therapeutically effective amount of the pharmaceutical composition of claim 16.

### Claim 23 (depends on 22)

The method of claim 22 wherein the antibody is administered in conjunction with a second therapeutic agent.
